Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 225Ac-DOTA-Daratumumab |
Synonyms | |
Therapy Description |
225Ac-DOTA-Daratumumab is a radioconjugate comprising daratumumab, a monoclonal antibody that targets CD38, linked to the radionuclide Actinium-225, which delivers radiation to tumor cells, potentially resulting in cytotoxic effects and inhibition of tumor growth (PMID: 31413916, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
225Ac-DOTA-Daratumumab | [225Ac]-DOTA-Daratumumab | 225Ac-DOTA-Daratumumab is a radioconjugate comprising daratumumab, a monoclonal antibody that targets CD38, linked to the radionuclide Actinium-225, which delivers radiation to tumor cells, potentially resulting in cytotoxic effects and inhibition of tumor growth (PMID: 31413916, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05363111 | Phase I | 225Ac-DOTA-Daratumumab | Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT06287944 | Phase I | Melphalan Fludarabine Sirolimus 225Ac-DOTA-Daratumumab Tacrolimus | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | Not yet recruiting | USA | 0 |